Advanced bone and soft tissue malignant tumors are malignant tumors that have developed metastases to other parts of the body than the primary site, especially lung metastases. For this type of patients, traditional treatments including surgery, chemotherapy and radiotherapy have very limited effects, and how to improve the survival rate of these patients has been the goal of international and domestic bone and soft tissue tumor experts. For advanced bone and soft tissue malignant tumors, a global multicenter collaborative clinical study of “AP23573” has been launched, bringing hope to patients with advanced bone and soft tissue malignant tumors. AP23573 is a rapamycin analog developed by ARIAD Pharmaceuticals (UK), which has been shown to have antiproliferative activity against a variety of tumors. AP23573 exerts antitumor activity by inhibiting mTOR, which inhibits protein production and cell growth. Results from preclinical studies have shown that AP23573 has a favorable safety profile and has antitumor activity against a variety of cancers, including sarcomas. For patients who have already benefited from cytotoxic chemotherapy, the drug is expected to further delay disease progression and ultimately improve patient survival. The global multicenter Phase III controlled clinical study of the program has started in 2007 and has enrolled more than four hundred patients by 2009, from the United States, the United Kingdom, France, Germany, Sweden, Italy, the Netherlands, South Korea, New Zealand and other countries, bringing new hope to patients with advanced bone and soft tissue sarcomas. The study has been initiated to accept eligible patients with advanced bone and soft tissue sarcoma for enrollment, and enrolled patients can receive free drug treatment and related clinical examinations, five consecutive days a week, once a day by mouth.